MétaCan
Menu
← Back to cohort

S1944 Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

2024· article· en· W4403721253 on OpenAlexaboutno aff
Sarah Park, Yael Wollstein, Alan L. Hutchison, Sonali Paul

Bibliographic record

VenueThe American Journal of Gastroenterology · 2024
Typearticle
Languageen
FieldMedicine
TopicLiver Disease Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineDiseaseFatty liverClinical trialInternal medicineLiver diseaseIntensive care medicine

Abstract

fetched live from OpenAlex

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are the second leading indications for liver transplant in the United States. The prevalence is unevenly distributed across ethnic groups with 22.3% of Hispanic patients disproportionately affected in the United States. This study aimed to assess racial and ethnic diversity among MASLD clinical trials. Methods: We performed a systematic review of randomized controlled trials (RCTs) of MASLD/MASH therapies in the US and Canada from 2005-2024. Multinational RCTs involving the US were included. Data including patient age, sex, race/ethnicity, and therapeutic intervention type were collected. Meta-analysis was used to determine the pooled prevalence of different racial and ethnic groups. Descriptive statistics were used to compare racial and ethnic trial inclusion to previously reported MASLD prevalences in the US. Results: Ninety-one RCTs met inclusion criteria. The studied therapeutics included medications (n=84), lifestyle interventions (n=6), and fecal microbiome transplant (n=1). When reported, the median age of study participants was 52.6 years (24.1 - 69.7) with 58% female subjects. Seventy-8 studies (85.7%) reported racial data and fifty-6 (61.5%) included ethnicity data. Among the 16,111 patients enrolled in these trials, 3,298 (20.5%) were of Hispanic ethnicity. Meta-analysis revealed a pooled prevalence of 78.8% in White patients (95% CI 72.9 – 84.6, I2 = 97%), 6.2% in Asian patients (95% CI 4.15 – 8.31, I2 = 94%), and 2.5% in Black patients (85% CI 1.58 – 3.44, I2 = 70%). Pooled prevalence of Hispanic patients was 31.7% (95% CI 26.8 - 36.6, I2 = 94.6%). This prevalence was higher than the reported national Hispanic prevalence of 22.3%, which may be partially explained by the substantial heterogeneity in the analysis. Hispanic enrollment also increased over time from 20% (2009 – 2014), 31% (2015 – 2019), to 35% (2020 – 2024). Conclusion: While the majority of studies reported data on participant race, only 61.5% included ethnicity. Since MASLD disproportionately affects Hispanic patients, it is imperative that clinical trials make a targeted effort to diversify patient recruitment. Compared to previous efforts, this study shows that trials are increasingly including Hispanic patients, yet need to increase inclusion of ethnicity data (see Figure 1).Figure 1.: Pooled prevalence of Hispanic patients among studies that reported ethnicity data.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.054
metaresearch head score (Gemma)0.090
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.946
Threshold uncertainty score0.286

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0540.090
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0050.009
Bibliometrics0.0020.003
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0010.001
Research integrity0.0030.001
Insufficient payload (model declined to judge)0.0200.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.098
GPT teacher head0.391
Teacher spread0.293 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicLiver Disease Diagnosis and Treatment→French-language works237,207→